William Blair Analysts Decrease Earnings Estimates for Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Zevra Therapeutics, Inc. (NASDAQ:ZVRAFree Report) – Stock analysts at William Blair reduced their FY2024 earnings estimates for Zevra Therapeutics in a research note issued on Wednesday, March 27th. William Blair analyst T. Lugo now expects that the company will post earnings per share of ($1.50) for the year, down from their previous estimate of ($1.08). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.38) per share.

Other analysts have also recently issued research reports about the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zevra Therapeutics in a report on Friday, January 12th. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Zevra Therapeutics in a report on Tuesday, March 5th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $20.00.

Check Out Our Latest Stock Analysis on Zevra Therapeutics

Zevra Therapeutics Stock Performance

NASDAQ:ZVRA opened at $5.80 on Friday. The stock has a market cap of $210.08 million, a P/E ratio of -4.50 and a beta of 1.82. The firm’s fifty day simple moving average is $6.18 and its 200 day simple moving average is $5.38. Zevra Therapeutics has a twelve month low of $3.89 and a twelve month high of $7.28. The company has a quick ratio of 6.31, a current ratio of 6.31 and a debt-to-equity ratio of 0.65.

Hedge Funds Weigh In On Zevra Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ZVRA. Vanguard Group Inc. bought a new position in Zevra Therapeutics during the 3rd quarter valued at about $7,772,000. Janney Montgomery Scott LLC purchased a new stake in Zevra Therapeutics in the 3rd quarter worth approximately $3,250,000. Retirement Planning Co of New England Inc. purchased a new stake in Zevra Therapeutics in the 3rd quarter worth approximately $1,674,000. Northern Trust Corp purchased a new stake in Zevra Therapeutics in the 3rd quarter worth approximately $1,304,000. Finally, Armistice Capital LLC purchased a new stake in Zevra Therapeutics in the 4th quarter worth approximately $1,755,000. Institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

(Get Free Report)

Zevra Therapeutics, Inc, a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.

Featured Articles

Receive News & Ratings for Zevra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zevra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.